Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;3(12):e2029058.
doi: 10.1001/jamanetworkopen.2020.29058.

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Ning Rosenthal  1 , Zhun Cao  1 , Jake Gundrum  1 , Jim Sianis  1 , Stella Safo  1
Affiliations

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Ning Rosenthal et al. JAMA Netw Open. .

Erratum in

  • Error in References Section.
    [No authors listed] [No authors listed] JAMA Netw Open. 2021 Jan 4;4(1):e2036103. doi: 10.1001/jamanetworkopen.2020.36103. JAMA Netw Open. 2021. PMID: 33443575 Free PMC article. No abstract available.

Abstract

Importance: Coronavirus disease 2019 (COVID-19) has infected more than 8.1 million US residents and killed more than 221 000. There is a dearth of research on epidemiology and clinical outcomes in US patients with COVID-19.

Objectives: To characterize patients with COVID-19 treated in US hospitals and to examine risk factors associated with in-hospital mortality.

Design, setting, and participants: This cohort study was conducted using Premier Healthcare Database, a large geographically diverse all-payer hospital administrative database including 592 acute care hospitals in the United States. Inpatient and hospital-based outpatient visits with a principal or secondary discharge diagnosis of COVID-19 (International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis code, U07.1) between April 1 and May 31, 2020, were included.

Exposures: Characteristics of patients were reported by inpatient/outpatient and survival status. Risk factors associated with death examined included patient characteristics, acute complications, comorbidities, and medications.

Main outcomes and measures: In-hospital mortality, intensive care unit (ICU) admission, use of invasive mechanical ventilation, total hospital length of stay (LOS), ICU LOS, acute complications, and treatment patterns.

Results: Overall, 64 781 patients with COVID-19 (29 479 [45.5%] outpatients; 35 302 [54.5%] inpatients) were analyzed. The median (interquartile range [IQR]) age was 46 (33-59) years for outpatients and 65 (52-77) years for inpatients; 31 968 (49.3%) were men, 25 841 (39.9%) were White US residents, and 14 340 (22.1%) were Black US residents. In-hospital mortality was 20.3% among inpatients (7164 patients). A total of 5625 inpatients (15.9%) received invasive mechanical ventilation, and 6849 (19.4%) were admitted to the ICU. Median (IQR) inpatient LOS was 6 (3-10) days. Median (IQR) ICU LOS was 5 (2-10) days. Common acute complications among inpatients included acute respiratory failure (19 706 [55.8%]), acute kidney failure (11 971 [33.9%]), and sepsis (11 910 [33.7%]). Older age was the risk factor most strongly associated with death (eg, age ≥80 years vs 18-34 years: odds ratio [OR], 16.20; 95% CI, 11.58-22.67; P < .001). Receipt of statins (OR, 0.60; 95% CI, 0.56-0.65; P < .001), angiotensin-converting enzyme inhibitors (OR, 0.53; 95% CI, 0.46-0.60; P < .001), and calcium channel blockers (OR, 0.73; 95% CI, 0.68-0.79; P < .001) was associated with decreased odds of death. Compared with patients with no hydroxychloroquine or azithromycin, patients with both azithromycin and hydroxychloroquine had increased odds of death (OR, 1.21; 95% CI, 1.11-1.31; P < .001).

Conclusions and relevance: In this cohort study of patients with COVID-19 infection in US acute care hospitals, COVID-19 was associated with high ICU admission and in-hospital mortality rates. Use of statins, angiotensin-converting enzyme inhibitors, and calcium channel blockers were associated with decreased odds of death. Understanding the potential benefits of unproven treatments will require future randomized trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors worked on the study as full-time employees of Premier Inc. No other disclosures were reported.

References

    1. US Centers for Disease Control and Prevention . CDC COVID data tracker. Accessed on November 19, 2020. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
    1. Holshue ML, DeBolt C, Lindquist S, et al. ; Washington State 2019-nCoV Case Investigation Team . First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-936. doi:10.1056/NEJMoa2001191 - DOI - PMC - PubMed
    1. Piva S, Filippini M, Turla F, et al. . Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020;58:29-33. doi:10.1016/j.jcrc.2020.04.004 - DOI - PMC - PubMed
    1. Rubino S, Kelvin N, Bermejo-Martin JF, Kelvin D. As COVID-19 cases, deaths and fatality rates surge in Italy, underlying causes require investigation. J Infect Dev Ctries. 2020;14(3):265-267. doi:10.3855/jidc.12734 - DOI - PubMed
    1. Xia XY, Wu J, Liu HL, Xia H, Jia B, Huang WX. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19. J Clin Virol. 2020;127:104360. doi:10.1016/j.jcv.2020.104360 - DOI - PMC - PubMed

Publication types

MeSH terms